Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant and Amyloid-Beta Kinetics in Sleep
NCT03077620Completed
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of suvorexant in Alzheimer's disease (AD) (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Difference in Amyloid-beta Concentration in the CSF of Individuals With Poor Sleep Efficiency Compared to Those With Good Sleep Efficiency at 36 hours and Difference in Amyloid-beta Concentration in the CSF of Individuals With Poor Sleep Efficiency Treated With Placebo, Suvorexant 10 mg, or Suvorexant 20 mg at 36 hours. Started Nov 2016; status: completed.
02
Drugs
suvorexant
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03077620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077620.